Millions of people living with osteoarthritis face a frustrating reality: standard treatments often fall short of providing meaningful, lasting relief. For those caught between conservative care and surgical intervention, intra articular injection hyaluronic acid therapy has emerged as a compelling middle-ground option, yet it remains one of the most debated treatments in musculoskeletal medicine.
Hyaluronic acid, a naturally occurring substance that gives healthy joint fluid its lubricating and shock-absorbing properties, has been used as an injectable therapy for decades. But does the clinical evidence actually support its widespread use? The answer, as with most things in medicine, is more nuanced than a simple yes or no.
In this analysis, we will break down what current research reveals about the efficacy, safety profile, and appropriate patient selection for hyaluronic acid injections. We will examine the strongest studies, acknowledge where the data falls short, and help you understand how to interpret conflicting findings. Whether you are a clinician refining your practice or a patient researching your options, this evidence-based review will give you the clarity you need.
What Is an Intra-Articular Hyaluronic Acid Injection?
Hyaluronic acid (HA) is a naturally occurring biopolymer produced by synoviocytes, the specialised cells that line the inner surface of joint cavities. In a healthy joint, HA is a foundational component of synovial fluid, giving it the thick, gel-like consistency that enables two critical mechanical functions: lubrication of the articulating cartilage surfaces and absorption of compressive forces during movement and weight-bearing. This combination of properties is described clinically as viscoelasticity, meaning the fluid behaves simultaneously as a viscous liquid and an elastic solid depending on the load applied to it.
In osteoarthritis (OA), this natural system breaks down. Both the concentration and molecular weight of HA within the synovial fluid decline significantly, producing a thinner, more watery environment that is far less capable of protecting the joint. As the viscoelastic properties deteriorate, cartilage surfaces experience greater mechanical stress, accelerating wear and triggering further inflammatory changes within the joint. The result is a progressive cycle of degradation that extends beyond simple “wear and tear” to involve synovitis, cartilage breakdown, and subchondral bone remodelling.
Viscosupplementation is the clinical approach designed to interrupt this cycle by injecting exogenous HA directly into the joint space to restore the mechanical and biological properties of the depleted synovial fluid. A useful way to visualise this: think of the synovial fluid as the lubricating oil inside a bearing. When that oil becomes thin and degraded, the moving surfaces begin to grind. An HA injection effectively replenishes that lubricating medium, restoring the protective cushioning layer between the joint surfaces. According to research published via the NIH, the effects can extend well beyond the physical half-life of the injected HA, suggesting a biological dimension to its action.
A common question is how HA injections differ from corticosteroid (steroid) injections. The distinction is clinically important. Steroid injections work by suppressing inflammatory mediators rapidly, making them effective for acute pain and inflammatory flares, typically within the first few weeks. HA injections, by contrast, target the mechanical environment of the joint rather than inflammation directly, with benefits building over a longer timeframe and typically sustained over several months. As meta-analysis data comparing both injection types illustrates, each has a distinct role in the management of knee OA, and the two approaches are increasingly being considered as complementary rather than interchangeable.
Which Joints Can Be Treated with Hyaluronic Acid Injections?
While the knee dominates the clinical literature on intra-articular hyaluronic acid, IAHA is applied across several joints, each with its own evidence base and clinical considerations.
The Knee
The knee remains the most extensively researched joint for IAHA by a considerable margin. A 2022 systematic review published in Cureus analysed 38 randomised controlled trials encompassing 5,025 patients, with 57.9% of those trials conducted under double-blind conditions, reflecting a high degree of methodological rigour. This breadth of evidence has established IAHA as a clinically recognised option within multimodal knee osteoarthritis management, supported further by a 2025 umbrella review confirming its efficacy, safety, and cost-effectiveness across multiple systematic reviews and meta-analyses. Research published in 2026 is now examining how combining HA with PRP or corticosteroids may extend pain relief and improve outcomes beyond what either treatment achieves alone.
The Hip
IAHA is used clinically for hip OA, particularly in patients who are not surgical candidates or who are managing symptoms while awaiting specialist review. The hip joint presents a greater technical challenge than the knee due to its depth and surrounding soft tissue anatomy. For this reason, ultrasound guidance is considered essential to confirm accurate intra-articular needle placement. The evidence base for hip IAHA is smaller than that for the knee, though clinical use is well established within specialist sports medicine practice.
The Shoulder
The glenohumeral joint is another site where IAHA is applied, most commonly for glenohumeral osteoarthritis and rotator cuff-related shoulder pain. This application is particularly relevant for active and sporting patients who wish to manage symptoms and maintain function without surgical intervention. Shoulder-specific trial data is less extensive than knee literature, and advances in HA combination strategies continue to inform how clinicians approach this joint.
Ankle and Other Joints
Clinical interest in ankle IAHA is growing, particularly among athletes and active individuals affected by post-traumatic ankle OA, a common consequence of sporting injury. While the ankle evidence base is still maturing, it represents an important non-surgical option for patients seeking to preserve function and delay operative management.
It is important to note that evidence strength varies meaningfully by joint, and appropriateness depends on your specific clinical presentation. A thorough specialist assessment is essential before pursuing IAHA for any joint.
What Does the Evidence Say? A 2025 and 2026 Research Summary
The evidence base supporting intra-articular hyaluronic acid has strengthened considerably in recent years, with a cluster of high-quality publications in 2025 and 2026 providing clinicians with a more nuanced and comprehensive picture of its role in knee osteoarthritis management.
The 2025 Umbrella Review: Consolidating the Evidence
A landmark systematic umbrella review published in the Journal of Clinical Medicine (February 2025), authored by Glinkowski and Tomaszewski and indexed on PubMed (PMID 40004802), represents one of the most comprehensive aggregations of IAHA evidence to date. Rather than reviewing individual trials, this systematic umbrella review of intra-articular hyaluronic acid for knee OA synthesised findings across multiple existing systematic reviews and meta-analyses, evaluating IAHA’s efficacy, safety, and cost-effectiveness simultaneously. Its explicit aim was to examine innovations in formulation, comparative outcomes, and guideline variability, ultimately confirming IAHA’s place within multimodal treatment strategies for knee OA. The breadth of this approach gives its conclusions particular weight, as it accounts for the cumulative evidence rather than isolated study findings. A March 2025 Bayesian network meta-analysis published in the Journal of Orthopaedic Surgery and Research further extended this evidence base, examining the long-term effectiveness of intra-articular injectables for knee OA specifically, and positioning IAHA within a comparative framework alongside other injectable options.
Real-World Outcomes and Economic Value
Beyond symptomatic relief, the economic case for IAHA is increasingly difficult to overlook. Evidence from the Mordin 2021 systematic review of economic evaluations documents that repeated courses of IAHA delayed total knee arthroplasty by more than five years in some patients, a finding with profound implications for both patient quality of life and healthcare resource use. The same body of evidence demonstrated that IAHA reduced opioid prescriptions by 6% (P less than 0.001), a statistically significant outcome that positions viscosupplementation as a meaningful tool in reducing dependency on analgesics. When compared directly against NSAIDs, corticosteroids, and conservative care, IAHA was found to be cost-effective, reinforcing the argument for its inclusion in structured non-surgical pathways.
Combination Strategies and Evolving Practice
The February 2026 evidence-based review published in Orthopedic Reviews by Cao, Tang, and Tran reflects a broader shift in clinical thinking. Rather than treating IAHA as a binary choice, the review explores both monotherapy and combination approaches, notably HA combined with PRP and HA combined with corticosteroids, as clinically distinct strategies with different indications. This evolution aligns with how specialists at Pro Sports Medicine approach injection therapy: selecting and combining treatments based on individual patient presentation rather than applying a one-size-fits-all protocol.
Addressing Guideline Variability Honestly
It is important to acknowledge that international guidelines are not uniform on IAHA. Some bodies assign it a conditional recommendation, while others remain more cautious, reflecting genuine heterogeneity in the trial literature. However, guideline divergence does not equate to clinical inefficacy. The 2025 umbrella review was specifically designed to interrogate this variability, and its conclusions support IAHA within individualised, specialist-led pathways. For the right patient, assessed by an experienced sports medicine physician with access to diagnostic imaging and a full clinical picture, the evidence strongly supports IAHA as a valuable and well-tolerated component of comprehensive joint management.
Does the Type of Hyaluronic Acid Product Matter?
Not all hyaluronic acid products are created equal, and treating them as interchangeable is a clinical shortcut that the evidence no longer supports. A Bayesian network meta-analysis published in MDPI Biomedicines demonstrated that different molecular weights of IAHA produce meaningfully different clinical outcomes in knee osteoarthritis, reinforcing what experienced sports medicine clinicians have long observed in practice: the product selected matters as much as the procedure itself.
Molecular Weight and Why It Changes Outcomes
HA products span a spectrum from low molecular weight (LMW) through intermediate to high molecular weight (HMW) formulations. HMW products more closely replicate the viscoelastic properties of healthy synovial fluid, offering stronger mechanical lubrication and shock absorption within the joint. LMW products may act through different receptor-mediated anti-inflammatory pathways. This distinction carries direct clinical consequence. A systematic review covering 38 randomised controlled trials and 5,025 patients found that pain relief duration following IAHA ranged from as little as 5 weeks to up to one year, a variation wide enough to reflect genuine product-level differences rather than patient factors alone. Research published in Drugs R and D confirms that molecular weight directly influences viscosupplementation efficacy and the duration of intra-articular lubrication effects.
Manufacturing Origin and Patient Safety
A further distinction worth understanding is manufacturing origin. Traditional HA products were derived from rooster combs, a process that carries allergy risk for patients with sensitivities to poultry or eggs. Modern biofermentation-derived HA, produced via bacterial fermentation, eliminates this allergenic concern entirely and is now the preferred approach in clinical practice. For patients with relevant dietary or allergic histories, this distinction is an important part of pre-injection assessment, not an afterthought.
Evidence-Led Selection at Pro Sports Medicine
According to a comprehensive expert review of innovative intra-articular HA products, clinically meaningful product evaluation must span five domains: nociceptive pain, joint function, quality of life, structural integrity, and adverse effects. This is the standard our team works to. At Pro Sports Medicine, product selection is not a default protocol; it is a considered clinical decision informed by the patient’s OA grade, activity level, age, and individual health profile. This level of precision reflects the evidence-based approach advocated in leading critical literature reviews, which explicitly call for IAHA treatment tailored by disease stage and patient phenotype. Not all providers approach injection therapy with this degree of clinical rigour, and that difference in approach can meaningfully affect the outcome a patient experiences.
Who Is a Suitable Candidate for Hyaluronic Acid Injections?
Patient selection is arguably the most important determinant of outcome when it comes to intra-articular hyaluronic acid. Understanding who is likely to benefit, and who may not, requires an appreciation of disease severity, individual circumstances, and clinical history.
Understanding OA Severity: The Kellgren-Lawrence Scale
The Kellgren-Lawrence (KL) grading system is the standard radiographic tool used to classify the severity of osteoarthritis, scored from Grade 0 (no signs of OA) through to Grade IV (severe, end-stage disease). Think of it as a wear-and-tear spectrum. Grade I involves minor changes such as small bony spurs with no significant joint space narrowing. Grade II introduces more definite osteophyte formation with possible mild narrowing. Grade III reflects moderate narrowing and early bone surface changes, while Grade IV represents near-complete loss of joint space, often described as bone-on-bone arthritis.
The clinical evidence for IAHA is concentrated firmly within KL Grades I to III. A systematic review encompassing 38 randomised controlled trials and 5,025 patients found the studied population sat within this mild-to-moderate range, with a mean patient age of 60.28 years. This is clinically meaningful: in Grades I to III, sufficient joint space and residual cartilage exist for the injected HA to exert its viscoelastic and anti-inflammatory effects. In Grade IV, the structural environment of the joint is too compromised. At this stage, surgical intervention such as joint replacement is typically the more appropriate clinical pathway, and IAHA is unlikely to deliver meaningful relief.
Age, Activity Level, and Treatment Positioning
IAHA is particularly well-suited to two broad patient profiles. Active adults, including recreational athletes and those in physically demanding occupations, may wish to maintain function and delay surgical intervention while continuing to exercise and work. At the other end of the spectrum, older patients for whom surgery carries elevated anaesthetic or recovery risk represent a group in whom viscosupplementation can provide meaningful symptom management over an extended period. Economic evidence reinforces this: repeated IAHA courses have been shown to delay total knee arthroplasty by more than five years in some patients, a clinically and economically significant outcome.
In terms of treatment positioning, IAHA typically follows a period of conservative management. Physiotherapy, weight management, activity modification, and oral analgesia such as NSAIDs should generally be explored first. That said, clinical guidelines vary, and in appropriate individual cases, earlier consideration of IAHA may be clinically justified, particularly where conservative measures are poorly tolerated.
Contraindications to Be Aware Of
Several contraindications apply and must be assessed before proceeding. Active infection within the target joint is an absolute contraindication, as injection risks spreading infection further. Known hypersensitivity to hyaluronic acid, or a prior adverse reaction to an HA product, similarly precludes treatment. Where avian-derived HA preparations are being considered, patients with allergies to poultry or eggs require either a bacterially fermented alternative or careful clinical review. An active skin infection, open wound, or inflammatory skin condition overlying the intended injection site also prevents safe administration. Blood clotting disorders or current anticoagulation therapy increase the risk of procedural bleeding and require individual risk assessment.
It is essential to understand that this list is not a self-referral checklist. Appropriate candidacy for intra-articular hyaluronate injections is a clinical decision that requires thorough assessment, review of imaging such as X-ray or diagnostic ultrasound, and a detailed medical history taken by a qualified clinician. At Pro Sports Medicine, our sports medicine doctors and multidisciplinary team conduct this assessment comprehensively, ensuring that every patient who proceeds with treatment is genuinely suited to it, and that those who are not are directed toward more appropriate interventions without delay.
Why Ultrasound-Guided Injection Matters for Accuracy and Outcomes
The technique used to deliver an intra-articular hyaluronic acid injection matters as much as the product itself, yet it remains one of the least discussed aspects of treatment in patient-facing information. Understanding the distinction between landmark-guided and ultrasound-guided injection is essential for anyone considering this treatment.
In a landmark-guided, or blind, injection, the clinician positions the needle based on palpated anatomical landmarks alone. There is no real-time visualisation of where the needle tip sits. In an ultrasound-guided injection, live imaging confirms accurate placement within the joint space before and during delivery, allowing the clinician to observe the injectate entering the precise target tissue. These are fundamentally different procedures, and the clinical evidence reflects that.
What the Evidence Shows
A 2021 systematic review of 12 Level I randomised controlled trials, involving 1,431 patients and 1,315 knees, found that ultrasound-guided injections outperformed landmark-guided injections for accuracy in every head-to-head comparison study included. A review from the University of North Carolina School of Medicine reinforced this finding, noting that conventional palpation-guided injections frequently result in inaccurate needle placement into extra-articular tissue and adjacent structures. A 2024 umbrella review in the Journal of Rehabilitation Medicine confirmed the accuracy advantage of image-guided approaches across multiple joints, and noted that standardisation of ultrasound guidance is still far from universal in routine clinical settings.
The accuracy gap is particularly significant in anatomically complex joints such as the hip and shoulder, where depth, bony architecture and restricted access make blind targeting considerably less reliable than in the knee.
Why Accuracy Directly Affects Your Outcome
Hyaluronic acid is a viscous therapeutic agent. If deposited into periarticular soft tissue rather than the joint space, the intended dose does not reach the cartilage environment where it is needed, reducing or negating clinical benefit. Inaccurate placement is also associated with higher rates of post-injection flare and procedural discomfort. A 2020 clinical comparison of ultrasound-guided versus anatomically guided HA injection in knee osteoarthritis patients found significantly lower pain scores in the ultrasound group, with VAS scores of 0 to 3 compared to 3 to 5 in the landmark group (p less than 0.001).
How Pro Sports Medicine Approaches This
At Pro Sports Medicine, in-house diagnostic ultrasound capability means that image-guided injection delivery is embedded as standard practice, not offered as a premium add-on. Our clinical team carries dedicated musculoskeletal ultrasound expertise, allowing accurate joint assessment and injection guidance to be performed by the same specialists managing your care pathway. This is a meaningful quality differentiator that most general content about HA injections simply does not address.
If you are considering intra-articular hyaluronic acid for knee, hip, or shoulder osteoarthritis, it is worth asking directly: will my injection be ultrasound-guided, and is that included as standard? The evidence strongly suggests that how the injection is delivered determines whether the treatment reaches its intended target.
Hyaluronic Acid, PRP, or Arthrosamid: How to Choose the Right Injection
Not all injectable treatments work through the same mechanism, and understanding the distinctions between them is central to making a well-informed clinical decision. Three options now dominate the non-surgical injection landscape for joint degeneration: hyaluronic acid, platelet-rich plasma (PRP), and Arthrosamid. Each has a distinct evidence profile, a defined patient population, and a different treatment schedule.
Hyaluronic Acid (Viscosupplementation)
Hyaluronic acid remains the most established injectable option for mild to moderate knee osteoarthritis, with decades of clinical use and a growing body of contemporary evidence supporting its role in multimodal treatment. By restoring synovial fluid viscosity and elasticity, it directly addresses one of the core mechanical consequences of joint degeneration. Treatment typically requires a course of injections delivered over several weeks, with symptom relief commonly sustained for six to twelve months. Economically, HA compares favourably against NSAIDs, corticosteroids, and conservative management alone, and evidence demonstrates that repeated courses can delay total knee arthroplasty by more than five years in some patients.
PRP (Platelet-Rich Plasma)
PRP takes a fundamentally different biological approach. Derived from the patient’s own blood, it concentrates growth factors that support tissue repair and modulate intra-articular inflammation. This autologous mechanism makes it a compelling choice for younger, more active patients with early to moderate joint degeneration, particularly where tissue-level repair is a treatment priority alongside symptom relief. A systematic review and meta-analysis published in PMC confirms that multiple PRP injections produce meaningful improvements in pain and function, with evidence of superiority over HA at longer follow-up intervals for appropriately selected patients. PRP eligibility does carry clinical constraints; patients on anticoagulants, those with low platelet counts, or those with end-stage joint disease may not be suitable candidates.
Arthrosamid (Polyacrylamide Hydrogel)
For patients with moderate to severe OA where HA alone may be insufficient, Arthrosamid offers a longer-duration alternative delivered as a single injection. The polyacrylamide hydrogel integrates with synovial tissue to provide sustained mechanical cushioning, with durability data suggesting benefits may extend to five years or beyond. The single-injection protocol also reduces patient burden considerably for those unable or unwilling to commit to repeated treatment courses.
Combination Therapy and the Role of Specialist Assessment
An important development from the February 2026 evidence-based review published in Orthopedic Reviews is the growing support for HA combined with PRP as a synergistic strategy. The rationale is mechanically sound: HA provides immediate lubrication while PRP delivers bioactive growth factors for tissue-level repair. For certain patient profiles, this combined approach may outperform either treatment used independently.
Critically, selecting between these options is not a process patients should navigate alone. Factors including OA severity and grading, age, activity level, comorbidities, and treatment history all influence which approach is most appropriate. At Pro Sports Medicine, all three options are available within a structured, assessment-led pathway, ensuring that the decision is reached through specialist clinical evaluation rather than guesswork.
What to Expect Before, During, and After Your Injection
Before Your Appointment: Consultation, Imaging, and Informed Consent
At Pro Sports Medicine, every intra articular injection hyaluronic acid treatment begins with a thorough specialist consultation. Your clinician will take a detailed history of your symptoms, assess joint function, and review any existing imaging. X-ray or MRI provides objective grading of osteoarthritis severity and helps determine whether your presentation falls within the range most likely to respond to viscosupplementation; ultrasound assessment adds a layer of soft tissue evaluation that plain imaging alone cannot provide. Alongside this, your doctor will walk you through all available treatment options, including where HA sits within the broader injection landscape alongside PRP and Arthrosamid, and what the realistic expectations are. This last point matters. HA injections produce gradual, progressive improvement rather than rapid relief, and patients who understand this timeline from the outset tend to have a more positive overall experience.
During the Procedure: Precision-Guided Delivery
The injection itself is a straightforward, clinic-based procedure that typically takes between 15 and 30 minutes from preparation to completion. You will be positioned comfortably on the treatment couch, the skin over the target joint is cleaned thoroughly, and a local anaesthetic is applied to minimise discomfort. The clinician then uses real-time ultrasound guidance to confirm precise needle placement within the joint capsule before the hyaluronic acid is delivered. This image-guided approach is standard practice at Pro Sports Medicine; as covered in the preceding section on technique, ultrasound guidance significantly improves intra-articular accuracy compared to landmark-based methods, and this directly influences how effective the treatment is.
Immediately After: The First 48 Hours
Mild localised soreness or swelling at the injection site is common and typically settles within 24 to 48 hours. This is a normal physiological response and should not be confused with treatment failure. Patients are advised to avoid strenuous activity during this window; light, low-impact movement is generally fine and can actually support fluid distribution within the joint.
When Will You Feel the Benefit?
Most patients begin to notice meaningful symptom improvement between four and eight weeks post-injection. This gradual onset reflects how HA works, restoring viscoelastic properties and modulating the joint environment over time rather than providing an acute analgesic effect. This distinguishes it clearly from corticosteroid injections, which tend to act faster but typically offer relief measured in weeks rather than months.
Course Length and Re-Treatment
Depending on the HA product selected and your individual response, a treatment course may involve one to five injections. Repeat courses are well-supported clinically; the EUROVISCO Consensus Guidelines recommend re-injection strategies tailored to prior response and patient characteristics. The economic evidence adds important context here: sustained HA treatment has been shown to delay total knee replacement by more than five years in some patients, and to reduce opioid prescription rates by a statistically significant 6%. For patients managing long-term joint health, this represents a meaningful contribution to both quality of life and avoiding surgical risk.
HA Injections in the UK: NHS Availability and Private Treatment in Wales
For patients in Wales seeking treatment for knee osteoarthritis, understanding the NHS position on hyaluronic acid injections is an important starting point. NICE guideline NG226, published in October 2022, does not recommend intra-articular hyaluronic acid as a routine NHS treatment for knee OA. It is worth being clear about why: this position is primarily shaped by cost-effectiveness thresholds applied within NHS funding frameworks, not by a blanket clinical verdict that the treatment does not work. International guidelines tell a notably different story. The EUROVISCO expert consensus, published in late 2024, provides detailed patient-stratified recommendations explicitly supporting IAHA use in knee OA, and academic engagement with viscosupplementation remains active across peer-reviewed literature into 2025 and 2026. The clinical evidence continues to evolve, and for many patients, the NICE position simply means the treatment is not funded by the NHS, not that it lacks clinical merit.
This distinction matters enormously in the current NHS landscape in Wales. Orthopaedic waiting times across South Wales have become a significant clinical and public health issue, with waits for surgical review commonly extending to 18 months or beyond in many health board areas. For a patient experiencing progressive knee pain and functional decline, that waiting period is not a neutral interval. It carries real consequences: reduced mobility, increased reliance on analgesics, and in some cases worsening joint degeneration. Against this backdrop, accessing a clinically justified, non-surgical intervention privately is not a luxury decision. It is a pragmatic and evidence-informed response to a system under sustained pressure.
At Pro Sports Medicine, private IAHA is offered precisely for patients navigating this gap, whether waiting for NHS orthopaedic review or actively seeking to avoid surgery altogether. The clinical case for this approach is supported by meaningful outcome data. Research has demonstrated that repeated courses of IAHA can delay total knee arthroplasty by more than five years in some patients, and that treatment is associated with a statistically significant 6% reduction in opioid prescriptions (P less than 0.001). Within a UK healthcare context where opioid dependency is a recognised concern and surgical capacity is stretched, these figures carry real public health weight.
The scale of the underlying problem reinforces the relevance of accessible non-surgical options. Osteoarthritis affects an estimated 528 million people worldwide, with a lifetime risk of symptomatic knee OA of approximately 45%. This is not a niche condition. It is one of the most prevalent musculoskeletal diagnoses across Cardiff and South Wales, and it demands a treatment pathway that can meet patients where they are, with evidence-based care, delivered without delay.
Hyaluronic Acid Injections at Pro Sports Medicine, Cardiff
Pro Sports Medicine has been operating as a specialist sports medicine and injury clinic in Cardiff since 2008, founded on a straightforward but ambitious principle: every patient deserves the same standard of musculoskeletal care delivered to professional and elite athletes. That ethos shapes every aspect of how the clinic operates, from initial assessment through to treatment and rehabilitation, regardless of whether a patient is a competitive sportsperson or someone simply trying to manage a painful knee.
Central to that standard of care is the clinic’s multidisciplinary team. Sports Medicine Doctors, Physiotherapists, Orthopaedic Consultants, a Consultant Radiologist, Podiatrists, and Soft Tissue Therapists all contribute to a genuinely coordinated clinical pathway. Rather than navigating between separate providers, patients move through diagnosis, treatment planning, injection delivery, and structured rehabilitation within a single, joined-up environment. This integration has real implications for both clinical outcomes and patient experience, reducing delays and ensuring that every decision is informed by the full clinical picture.
A key feature of that environment is in-house musculoskeletal diagnostic ultrasound. At Pro Sports Medicine, ultrasound-guided injection delivery is standard practice, not an optional upgrade. Imaging and treatment can take place within the same consultation, allowing clinicians to review findings and proceed to injection with real-time precision guidance when appropriate.
The clinic offers a comprehensive range of injection therapies, including hyaluronic acid, PRP, Arthrosamid, corticosteroid, hydrodilation, and high volume injection. No single treatment is right for every patient; the most appropriate option is always selected based on individual factors including diagnosis, arthritis severity, health status, and personal goals. That clinical flexibility is what makes the approach meaningful rather than formulaic.
If you are managing joint pain and want to understand your options, the team at Pro Sports Medicine in Cardiff is happy to help. A consultation is the right starting point, and there is no pressure to commit to any particular treatment pathway before you are ready.
Frequently Asked Questions About Hyaluronic Acid Joint Injections
How long does a hyaluronic acid injection last?
Duration of benefit varies depending on the specific product used, its molecular weight, and individual patient factors such as disease severity and activity level. Most patients can expect meaningful symptom relief lasting between six and twelve months following a completed course. Higher molecular weight products tend to sustain their viscoelastic effect longer within the joint environment. Importantly, clinical evidence supports repeat courses where initial treatment has been effective, and repeated IAHA has been associated with delaying total knee arthroplasty by more than five years in some patients, which represents a significant quality-of-life benefit.
Is a hyaluronic acid injection painful?
The procedure is generally well tolerated. At Pro Sports Medicine, all injections are performed under ultrasound guidance, which improves needle placement accuracy and helps minimise procedural discomfort. A local anaesthetic is typically applied beforehand to numb the area. Some patients experience a mild post-injection flare, characterised by temporary soreness and minor swelling around the joint. This is a normal, short-lived response that usually settles within 24 to 48 hours and does not indicate a problem with the treatment.
How many injections do I need?
Course length depends on the product selected and your individual clinical presentation. Some modern formulations are designed as a single injection, while others involve a series of three to five weekly injections delivered over three to five weeks. Full benefit is typically experienced around five weeks after completing a course. The appropriate protocol is determined during your specialist consultation, where your clinician will assess imaging findings, symptom severity, and treatment history before recommending the most suitable approach.
Can I have a hyaluronic acid injection on the NHS?
This is one of the most commonly asked questions, and it deserves a straightforward answer. NICE guideline NG226 does not recommend intra-articular hyaluronic acid within NHS pathways for knee osteoarthritis. As a result, IAHA is not routinely available through NHS Wales and is accessed as a private treatment. For patients in Cardiff and across South Wales, this means self-funding or using private health insurance. A private specialist consultation is the appropriate first step, allowing a thorough assessment before any treatment is recommended.
What is the difference between hyaluronic acid and PRP injections?
Hyaluronic acid injections work by restoring the viscoelastic properties of synovial fluid, improving lubrication and shock absorption within the joint. The mechanism is primarily mechanical and anti-inflammatory through fluid supplementation. Platelet-rich plasma (PRP) takes a different approach; a small sample of your own blood is processed to concentrate growth factors, which are re-injected to support tissue repair and modulate inflammation. PRP is a regenerative intervention rather than a lubricative one. Both treatments have evolving evidence bases, and emerging research suggests combination protocols using both together may offer advantages over either alone. Selecting the right approach requires specialist assessment of your specific diagnosis, joint condition, and treatment goals.
Are there any side effects or risks?
IAHA is considered a low-risk procedure when performed by an experienced clinician under sterile, ultrasound-guided conditions. The most common adverse effect is a temporary post-injection flare with localised soreness and mild swelling, which resolves quickly. Less commonly, patients may experience bleeding at the injection site or a localised allergic reaction. Infection and septic arthritis are rare but serious risks, which is why active infection elsewhere in the body is a contraindication to injection. Pseudo-septic or severe inflammatory reactions are uncommon. Modern HA products derived from bacterial fermentation rather than avian sources significantly reduce the risk of hypersensitivity reactions linked to avian protein, making them the preferred option for most patients today.
Key Takeaways
Intra-articular hyaluronic acid stands as one of the most well-evidenced non-surgical options available for mild to moderate osteoarthritis. It works by restoring the viscoelastic properties of synovial fluid, reducing pain, improving joint function, and, with repeated courses, potentially delaying surgical intervention by more than five years. The evidence is meaningful and continues to grow, but outcomes depend heavily on how the treatment is delivered.
Specialist-led assessment, accurate diagnosis, and considered product selection are not optional extras; they are the foundation of a successful outcome. The molecular weight of the HA product used, the clinical profile of the patient, and the precision of the injection technique all influence results in ways a generic approach simply cannot account for.
Ultrasound guidance and a multidisciplinary clinical environment are practical markers of quality that patients should actively seek out. At Pro Sports Medicine in Cardiff, these are standard, not exceptions.
If you are managing joint pain and want a clear, honest, evidence-based recommendation on whether IAHA is right for your situation, a consultation with our specialist team is the logical next step. We will assess your joint, review relevant imaging, and provide a personalised treatment plan built around your goals.
